Background {#s1}
==========

As a common clinical condition, primary insomnia[@R1] is defined as a symptom of prolonged sleep latency, difficulties in maintaining sleep, the experience of non-refreshing or poor sleep coupled with impairments of daytime functioning,[@R2] including reduced alertness, fatigue, exhaustion, dysphoria and other symptoms. The Diagnostic and Statistical Manual of Mental Disorders further defines the condition to be not attributable to a medical, psychiatric or environmental cause. Chronic insomnia (with symptoms at least 3 nights a week for at least 1 month) presents a substantially increased risk for other psychiatric disorders, especially depression,[@R3] as well as for cardiovascular morbidity and mortality.[@R4] The prevalence of insomnia disorder is approximately 10--20%, with approximately 50% having a chronic course.[@R5]

Although primary insomnia is considered a sleep disorder, its pathophysiology suggests hyperarousal during sleep and wakefulness.[@R6] Evidence of hyperarousal in insomniacs includes elevated whole-body metabolic rate during sleep and wakefulness, elevated cortisol and adrenocorticotropic hormone during the early sleep period, reduced parasympathetic tone in heart rate variability and increased high-frequency electroencephalographic activity during non-rapid eye movement sleep.[@R7] Genetic, environmental, behavioural and physiological factors have been proposed to contribute to the aetiology and pathophysiology of hyperarousal-induced insomnia.[@R5]

For chronic insomnia, hypnotic medications (benzodiazepine receptor agonists in particular) and cognitive-behavioural therapy (CBT) have been first-line treatments. Although benzodiazepine receptor agonists are efficacious in the short-term management of insomnia, there is very limited evidence of their long-term treatment efficacy.[@R8] Also, various adverse effects related to their use have been reported, including residual daytime sedation, cognitive impairment and medication dependence.[@R9] CBTs, although clinically effective, are not widely used due to intense labour and lack of trained therapists.[@R9] The guidance for clinicians in choosing the best treatment is limited so far, and the search for better treatment modality is ongoing.

As a major component of traditional Chinese medicine (TCM), acupuncture has been used in the treatment of insomnia in China for thousands of years. The systematic reviews indicated that acupuncture could be effective against insomnia. New comprehensive and more strictly designed clinical studies, meanwhile, were encouraged to give more evidence.[@R10]

The previous trials of treatment of insomnia mostly focused on the effects of sleep quality; daytime functioning was not highly considered. Our pilot study suggested that verum acupuncture was more effective in increasing sleep quality and daytime functioning than sham acupuncture.[@R14] Huang\'s systematic review indicated that acupuncture could modulate autonomic tone and central activation by its direct effects on peripheral nerves and muscles. Acupuncture may have great relevance for the modulation of sleep and wakefulness via a potential neural and/or hormonal mechanism.[@R15]

It has been suggested that patients with insomnia may benefit from treatment of their arousal level.[@R16] However, the hyperarousal state was not evaluated in previous trials. On the basis of the results of our previous study and the consideration that acupuncture may reduce the level of hyperarousal, we designed this randomised controlled trial to investigate the efficacy of acupuncture on sleep quality and hyperarousal state for insomnia. A hyperarousal state will be assessed multidimensionally, including cognitive functions, autonomic nervous system activities and hypothalamic pituitary adrenocortical (HPA) axis functioning.

Heart rate variability (HRV) is a tool for autonomic nervous system (ANS) activity monitoring. It has been demonstrated that patients with insomnia showed modifications of heart rate and HRV parameters, consistent with increased sympathetic activity.[@R17] Bonnet and Arand[@R18] have found increased low-frequency power (LF) and decreased high-frequency power (HF) in insomniacs compared with contro1 across all sleep stages. Acupuncture has been shown to modify autonomic nervous system activities, as indicated by changes in HRV LF, HF as well as their ratio (LF/HF) in various studies.[@R19] Therefore, we will use HRV as a tool to observe how acupuncture affects the ANS related to sleep cycles in this trial.

Insomnia has also been associated with a 24 h increase of adrenocorticotropic hormone and cortisol secretion, consistent with a disorder of central nervous system hyperarousal.[@R22] Morning salivary cortisol level (MSCL) is correlated with sleep parameters.[@R23] We will monitor its change via acupuncture as an indication of effects on HPA axis.

Methods {#s2}
=======

Objective {#s2a}
---------

To demonstrate if acupuncture is an effective therapy for primary insomnia in association with a decreased hyperarousal level as a possible underlying mechanism.

Hypotheses {#s2b}
----------

1.  The verum acupuncture intervention, compared with the sham acupuncture intervention, will significantly improve sleep quality, as indicated by both subjective (Pittsburgh Sleep Quality Index, PSQI) and objective (polysomnography, PSG) measurements after treatment.

2.  Sleep improvements will be associated with changes of hyperarousal state, as measured by Hyperarousal scale (HAS), HRV and MSCL.

3.  The verum acupuncture intervention, compared with the sham acupuncture intervention, will significantly reduce levels of fatigue during the daytime.

Trial design {#s2c}
------------

This is a patient-assessor-blinded, single-centre, randomised and sham controlled trial which conforms to the CONSORT (Consolidated Standards of Reporting Trials)[@R24] and STRICTA (Standards for Reporting Interventions in Clinical Trials of Acupuncture) guidelines[@R25] for acupuncture studies.

Participants and recruitment {#s2d}
----------------------------

Participants will be recruited from the outpatient clinic of Beijing TCM Hospital. Assuming a 20% dropout rate, a total of 88 eligible patients will be randomised in a ratio of 1:1 to the invention and control group and receive treatments for 4 weeks.

Inclusion criteria {#s2e}
------------------

1.  Over 18 and under 65 years old

2.  Primary insomnia by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV-TR) criteria

3.  Reports of clinical symptoms of persistent insomnia (3 or more nights per week) for 3 months or longer

4.  Score of 8 or above on the PSQI, 33 or above on the HAS

5.  Not being treated with psychoactive medications

6.  No problem with communication and intelligence

7.  Signed the written informed consent form for the clinical trial

Exclusion criteria {#s2f}
------------------

1.  Diagnoses of epilepsy, diabetes mellitus, cardiovascular disease, kidney failure, hypertension, metabolic diseases or benign prostatic hyperplasia

2.  Diagnoses of depression, anxiety, schizophrenia or other severe mental disorders

3.  Diagnoses of other sleep disorders, or discovery of any other sleep disorder on PSG at the baseline, such as obstructive sleep apnoea, rapid eye movement (REM) sleep disorder or restless legs syndrome

4.  Pregnancy, breastfeeding or woman of childbearing age not on a proper method of birth control

5.  Has had acupuncture for insomnia treatment in the past month

6.  Alcohol and/or other drug abuse or dependence

Randomisation and allocation concealment {#s2g}
----------------------------------------

The central randomisation will be performed by the Research Center of Clinical Epidemiology, the Peking University Third Hospital. The random allocation sequence was generated with a block of 4. Randomisation numbers will be sealed in a predetermined computer-made randomisation opaque envelope. The patients' screening sequence numbers will be printed outside the envelope, whereas the group names will be printed inside. All envelopes will be numbered consecutively and connected. Researchers who screen the eligible patients after baseline will separate the envelopes from the strain and open them according to the patients' screening sequence numbers, and then assign the patients to either the treatment group or the control group.

Blinding {#s2h}
--------

This is a patient-assessor-blinded trial, in which patients are not aware of their group assignments. The follow-up assessors will be blinded to the patients' group assignments as well. Although acupuncturists will not be blinded to the group assignments, they will not be involved in the outcome assessments or data analyses.

To achieve blinding, both real and sham acupuncture groups will use the same kind of disposable, sterile steel needles (1.5-infiliform needle, 0.32 mm×40 mm); same number of needles per session (10--12 needles); same skin disinfection process with 75% alcohol; and retention for 30 min.

Intervention {#s3}
============

Intervention group {#s3a}
------------------

Participants in the intervention group will receive acupuncture therapy three times a week for 4 weeks (shown in [table 1](#BMJOPEN2015009594TB1){ref-type="table"}). Du-20, DU-24, GB-13 and EX-HN1 will be punctured at a depth of 10 mm obliquely. SP-6 will be punctured 10 mm straightly, while PC6 and HT-7 will be inserted 5 mm perpendicularly. Needle manipulation will be applied to achieve 'De Qi'. Needle retention will be 30 min.

###### 

Details of interventions

                                                 Intervention group                                                                                                                      Control group
  ---------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------
  Points                                         Baihui (DU-20), Shenting (DU-24), Benshen (GB-13), Sishencong (EX-HN1), Neiguan (PC6), Sanyinjiao (SP6), Shenmen(HT7), all unilateral   Binao (LI-14), Shousanli (LI-10), Yangchi ((SJ4), Waiguan (SJ5), Fengshi (GB31), Futu (ST32) and Liangqiu (ST-34), all unilateral.
  Depth description                              Depth of needle insertion was at least 5--10 mm                                                                                         Depth of needle insertion was at 2 mm
  Needle retention time                          30 min                                                                                                                                  30 min
  Needle type                                    Stainless steel needles (0.32×40 mm, HuaTuo, China)                                                                                     Stainless steel needles (0.32×40 mm, HuaTuo, China)
  Frequency and duration of treatment sessions   Three times a week for 4 weeks                                                                                                          Three times a week for 4 weeks
  Needle stimulation                             De-qi sensation felt by practitioner and patient                                                                                        Without De-qi sensation

Control group {#s3b}
-------------

Participants in the control group will receive sham acupuncture therapy three times a week for 4 weeks. Sham acupuncture will be conducted by needling the acupoints of LI-14, LI-10, SJ4, SJ5, GB31, ST32 and ST-34. Stainless steel needles of the same specifications as the intervention group will be inserted superficially at a depth of 1 mm at the acupuncture points and kept for 30 min. According to the literature review, the acupoints in the control group have no therapeutic effect for insomnia. Meanwhile, manual stimulation and De qi will be avoided to minimise its placebo effect.

Outcome measures {#s3c}
----------------

(All outcome measures are shown in [table 2](#BMJOPEN2015009594TB2){ref-type="table"} and [figure 1](#BMJOPEN2015009594F1){ref-type="fig"}). PSQI, HAS, Sleep Diary, Fatigue scale (FS-14), PSG, HRV and MSCL will be the outcomes used to assess efficacy. Adverse events will be recorded to assess safety.

###### 

Time of visits and data collection

                              Baseline   Treatment phase   Follow-up phase 8th week       
  --------------------------- ---------- ----------------- -------------------------- --- ---
  Patients                                                                                
   EEG                        ×                                                           
  HAMA,HAMD                   ×                                                           
  Sign the informed consent              ×                                                
  Medical history             ×                                                           
  Randomisation                          ×                                                
  Intervention                           ×                 ×                          ×   
  Sleep diary                 ×                                                       ×   ×
  Primary outcomes                                                                        
   PSQI                       ×                                                       ×   ×
   HAS                        ×                            ×                          ×   ×
  Secondary outcomes                                                                      
   FS-14                                 ×                 ×                          ×   ×
   PSG+HRV                               ×                                            ×   
   MSCL                                  ×                                            ×   
  Adverse events                                           ×                          ×   ×

FS-14, Fatigue scale-14; HAMA, Hamilton Anxiety scale; HAMD, Hamilton Depression scale; HAS, Hyperarousal scale; HRV, heart rate variability; MSCI, morning salivary cortisol level; PSG, polysomnography; PSQI, Pittsburgh Sleep Quality Index.

![Flow chart of study process. FS-14, Fatigue scale-14; HAMA, Hamilton Anxiety scale; HAMD, Hamilton Depression scale; HAS, Hyperarousal scale; HRV, heart rate variability; MSCI, morning salivary cortisol level; PSG, polysomnography; PSQI, Pittsburgh Sleep Quality Index.](bmjopen2015009594f01){#BMJOPEN2015009594F1}

Primary outcome {#s3d}
---------------

### Pittsburgh Sleep Quality Index {#s3d1}

The PSQI is a self-rated questionnaire that assesses sleep quality and disturbance over a 1-month time interval.[@R26] The items are divided into seven 'component' scores: sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication and daytime dysfunction. A lower global score reflects a better quality of sleep.[@R27]

### Hyperarousal scale {#s3d2}

The HAS is a 26-item self-report that measures information processing, tendencies to introspect, think about feelings, respond intensely to unexpected stimuli, and other behaviours that putatively involve cortical arousal.[@R28] The higher the scores, the more heightened the state of arousal. A normal mean HAS score was reported to be 30.8.[@R29] HAS can be used to assess the effect on cognitive and somatic hyperarousal.[@R30]

Secondary outcome {#s3e}
-----------------

### Sleep diary {#s3e1}

One-week sleep diaries will be collected at baseline, 3 weeks after treatment and at the end of the follow-up. Patients will be asked to estimate the time taken to go to bed on the previous night, wake-up time, the time it took to fall asleep, the number of times they awoke after sleep onset, the feeling after getting up, total sleep time, factors that interfere with sleep, etc.

### Fatigue scale-14 {#s3e2}

Fatigue is one of the main consequences of chronic insomnia reported by previous studies.[@R31] FS-14 is a standardised questionnaire[@R31] to reflect physical fatigue and mental figure. The higher the score, the worse the level of fatigue is.

### Polysomnography {#s3e3}

All patients will be evaluated for three nights (2 nights at 0 week and 1 night at 4th week) in a sleep laboratory with sound-attenuated, light-controlled and temperature-controlled rooms. During this evaluation, patients will be allowed to sleep ad libitum based on their habitual sleep time, with the recording time range from 22:00 to 7:00. This procedure included the following: EEG, bilateral electroculogram, submental electromyogram, oronasal airflow, thoracic and abdominal movements, arterial oxygen saturation (SaO~2~), snoring, ECG, leg movements and body position recordings. All PSG data will be collected and stored using an E-Series digital system (Compumedics, Abbotsford, Australia). All the computerised sleep data will be further edited by an experienced PSG technologist blinded to the group assignments. Sleep stages, respiratory events and periodic limb movements will be scored according to the American Academy of Sleep Medicine (AASM) Manual for the Scoring of Sleep and Associated Events V.2.0.[@R34]

### Heart rate variability {#s3e4}

The HRV study will be carried out on the EKG trace obtained in the PSG study during night-time and 24 h-long distance Holter monitor at baseline and post-treatment. Sampling rate will be 256 Hz, with a digital resolution of 16 bits per sample. Impedance will be kept below 5 KΩ. HRV will be evaluated at different sleep stages defined by PSG.

### Morning salivary cortisol level {#s3e5}

Patients will be required to provide one saliva specimen collection between 06:00--08:00 (30 min after awakening) at baseline and after treatment. The collection tubes will be kept in a −20°C freezer until being shipped to a laboratory (Zhongtonglanbo Clinical Examination Laboratories, Beijing) for analysis by chemiluminescence immunoassay. Patients will be told not to eat, drink, brush their teeth or engage in strenuous activity 1 h before saliva sampling.

### Other outcome {#s3e6}

Any adverse events (described as unfavourable or unintended signs, symptoms or diseases occurring after treatment) related to acupuncture treatment will be observed and reported by patients and practitioners during each patient visit. In addition, all vital signs and adverse events will be measured and recorded at each visit.

### Setting {#s3e7}

The trial will be conducted in Beijing TCM Hospital between 1 June 2015 and 31 January 2017.This protocol has been approved by the Medical Ethical Committee of the Beijing TCM Hospital on 5 January 2015.The permission number is 2014BL-056--02.

[Figure 1](#BMJOPEN2015009594F1){ref-type="fig"} and [table 2](#BMJOPEN2015009594TB2){ref-type="table"} describe the trial protocol. The eligibility of prospective participants will be determined by a researcher who is not involved in the assessment or treatment of the participants.

On the first arrival for screening meeting, patients will be given more detailed information about the procedures of the study. An ECG test will be performed to test the heart rate. All patients will be required to complete the Hamilton Anxiety scale (HAMA), Hamilton Depression scale (HAMD), HAS. Subjective sleep outcome will be collected as measured by PSQI. Patients without an abnormal heart rate and obvious depression and anxiety, with a score of 8 or above on the PSQI and a score of 33 or above on the HAS will be diagnosed as patients with clinical insomnia. Inclusion and exclusion criteria will be reassessed. One-week sleep diaries will be required to be collected prior to their second visit for the baseline evaluation in order to see whether they had experienced insomnia recently.

On the second visit, an expert will check the patients' sleep diaries. If the patients really have experienced insomnia, they will be required to complete the test of PSG. The PSG is highly recommended as an objective tool for assessing insomnia. Patients without other sleep disorders such as obstructive sleep apnoea, REM sleep disorder and restless legs syndrome will be enrolled and registered into the clinical trial. They will be asked to provide written informed consent and complete the tests of FS-14, HRV and MSCL prior to first treatment.

Two weeks after the treatment, HAS will be measured again and changes in physical fatigue and mental fatigue will be observed using FS-14. Four weeks after the treatment, all patients will complete FS-14, HAS, PSQI, HRV, PSG and MSCL. 1-week sleep diaries will be collected 3 weeks after the treatment. At the end of the follow-up period, data of FS-14, HAS and the sleep diary for the 7th week will be collected for the last time. Results will be analysed by professionals blinded to the group allocation.

Statistical methods {#s4}
===================

Sample size {#s4a}
-----------

According to our previous pilot study, the global score of PSQI after 4 weeks' treatment in the acupuncture group was 8.60±2.25, and that in the control group was 9.83±1.88.[@R11] On the basis of 0.8 power to detect a significant difference (α=0.01, two-sided), 36 participants will be required for each group, which is calculated by PASS11. Allowing for a 20% withdrawal rate, we plan to enrol a total of 88 participants with 44 participants in each group.

Statistical analysis {#s4b}
--------------------

De-identified outcome data will be analysed by a statistician blinded to group allocations using the Statistical Package for the Social Sciences (SPSS) V.19.0 statistical software package. Significant levels will be set at p\<0.05.

Data analysis of baseline characteristics and of primary and secondary outcomes will be based on the intention-to-treat principle. χ^2^ Test will be conducted for the case of proportions and independent sample t tests will be analysed for testing the baseline differences between the two groups. A repeated-measures analysis of variance (ANOVA) will be used to compare the effect of real and sham acupuncture. Missing data will be replaced according to the principle of the last observation carried forward.

Patient safety {#s4c}
--------------

Any adverse events (described as unfavourable or unintended signs, symptoms or diseases occurring after treatment) related to acupuncture treatment will be observed and reported by patients and practitioners during each patient visit. In addition, all vital signs and adverse events will be measured and recorded at each visit.

Quality control {#s4d}
---------------

All acupuncturists and assessors will be required to undergo special training prior to the trial to guarantee consistent practices. The training programme will include diagnoses, inclusion and exclusion criteria, location of the acupuncture points, acupuncture manipulation techniques and completion of case report forms. Dropouts and withdrawals from the study will be recorded through the intervention and follow-up periods. This trial will be monitored by the scientific research department of Beijing TCM Hospital. Periodic monitoring will guarantee accuracy and quality throughout the study.

Discussion {#s5}
==========

The aim of this trial is to investigate the efficacy of acupuncture on sleep quality and hyperarousal state for primary insomnia. Effectiveness indicators will be subjective and objective sleep duration and quality, ANS functioning by HRV measurements, and physiological changes in HPA axis state by morning cortisol level measurement. This trial will attempt to associate the effects of acupuncture on primary insomnia with its effects on hyperarousal state measured at multiple dimensions. We believe that this will be the first attempt in a clinical trial of primary insomnia investigating clinical effects as well as possible underlying mechanisms of acupuncture.

HRV will be used to assess changes in the ANS. Different sleep stages may have differences in autonomic tone when it occurs in the proximity of SWS or REM sleep.[@R14] One of the strengths of this study is that we will measure HRV in each sleep stage separately. Using HRV and PSG together to evaluate HRV in different stages of wake and sleep, allowing a better description of the fluctuations of autonomic arousal of insomniacs in the course of the wake--sleep cycle.[@R17]

The use of an appropriate control group is critical in designing a high-quality clinical trial. Points selection is crucial for efficiency. The results of our previous trial have shown that the acupuncture points selected in the intervention group may improve both nocturnal sleep and daytime functioning. According to the literature review and clinical experiences, the acupoints in the sham group are mainly for local disease and have no therapeutic effect for insomnia.

In addition, the function of 'De qi' will be considered in the trial; it is based on subjective reporting of the patient (soreness, numbness, fullness, radiating sensation, etc) and is regarded as a sign of efficacy according to TCM. Most contemporary acupuncturists still seek De qi and believe it is fundamental to efficacy.[@R35] The placebo effect produced by sham acupuncture was considered to have less influence on the disease, although needle pricking might induce non-specific physiological reactions.[@R14]

Our study will produce data on the treatment of primary insomnia with acupuncture. The results will help to demonstrate if acupuncture is an effective therapy for improving sleep quality or not, while observing its possible mechanistic associations. We will test the hypothesis that the effect of acupuncture on insomnia will be associated with inhibiting the hyperarousal state. The results of the trial might guide better selective use of acupuncture modality as a treatment for insomnia in the future.
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